Nesiritide
Also known as: Natrecor, recombinant human BNP, rhBNP, B-type natriuretic peptide (recombinant), human BNP-32, nesiritide acetate
Recombinant natriuretic peptide — endogenous cardiac hormone analogue; balanced vasodilator / natriuretic agent
What it is
Nesiritide (Natrecor) is an FDA-approved intravenous medicine used in hospital to rapidly relieve the breathlessness and fluid congestion of acute heart failure. It works by relaxing blood vessels and promoting fluid removal, giving the failing heart a chance to recover. Used exclusively in supervised clinical settings.
The scientific side
nesiritide is a recombinant form of human B-type (brain) natriuretic peptide (BNP) whose amino acid sequence is identical to the 32-amino-acid endogenous cardiac hormone. Endogenous BNP is secreted by ventricular myocytes in response to elevated wall stress — increased preload, afterload, or pressure overload — and serves as a compensatory counter-regulatory hormone opposing the activated renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system that drive heart failure progression. Nesiritide exerts its effects by binding to guanylyl cyclase-coupled natriuretic peptide receptors (NPR-A and NPR-B) expressed on vascular smooth muscle, cardiac myocytes, the kidneys, adrenal glands, and the brain. Receptor binding activates intracellular guanylyl cyclase, elevating cyclic guanosine monophosphate (cGMP), which in turn triggers smooth muscle relaxation and vasodilation. The resulting hemodynamic profile is a balanced vasodilation of both the arterial and venous circulations: systemic vascular resistance falls (afterload reduction), pulmonary capillary wedge pressure and right atrial pressure decrease rapidly (preload reduction), and mean pulmonary artery pressure is lowered — all without a reflex increase in heart rate. These changes directly increase stroke volume and cardiac index in a manner that does not depend on direct myocardial inotropic stimulation, meaning nesiritide does not increase myocardial oxygen consumption — a key advantage over inotropes such as dobutamine. In the kidneys, nesiritide promotes natriuresis and diuresis through a direct renal tubular action, increased renal perfusion from improved cardiac output, and suppressed aldosterone secretion. Neurohormonal modulation is a further mechanism: nesiritide infusion measurably reduces circulating aldosterone, norepinephrine, endothelin-1, and plasma renin activity. Unlike nitroglycerin, tachyphylaxis to nesiritide has not been observed in clinical trials. In patients with heart failure, endogenous BNP levels are already elevated but the myocardium and vasculature develop relative resistance to its effects; exogenous recombinant BNP (nesiritide) overcomes this resistance by providing supraphysiologic receptor stimulation. Heart rate variability and reduced ventricular ectopy have also been documented with nesiritide infusion, consistent with its sympatholytic and anti-arrhythmic neurohormonal profile. Unlike phosphodiesterase-III inhibitors and beta-adrenergic agonists, nesiritide is not arrhythmogenic.
Class: Recombinant natriuretic peptide — endogenous cardiac hormone analogue; balanced vasodilator / natriuretic agent
Administration & storage
- Administration
- Intravenous bolus (prime tubing with infusionthen administer bolus over approximately 60 seconds from the IV bolus port)Continuous intravenous infusion via a dedicated IV line or through a separate catheter lumenDo not administer other medications through the same IV line as nesiritide; flush line with compatible IV solution before and after nesiritide infusionCentral or peripheral IV access acceptable; invasive hemodynamic monitoring (pulmonary artery catheter) used in some study protocols but not required per FDA label
- Storage
- Unreconstituted vials: store at 2–25°C (36–77°F); protect from light. Do not freeze. Reconstituted solution: stable for up to 24 hours at 2–25°C.
Legal & regulatory status
FDA-approved (NDA 020920) as Natrecor (nesiritide for injection) for the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity. Approved…
Nesiritide is not listed as a prohibited substance on the WADA Prohibited List. As a recombinant form of an endogenous cardiac peptide used exclusively for acute inpatient heart failure management, it does not confer…
Approved by Health Canada as Natrecor for the management of acute decompensated heart failure in patients with dyspnea at rest or with minimal activity. Regulatory status confirmed in clinical use literature; a Canadian…
What it's studied for
- Acute decompensated heart failure (ADHF) — hemodynamic improvement and dyspnea relief Phase III RCT
- Acute decompensated heart failure in patients with renal insufficiency Human RCT
- Comparative efficacy versus dobutamine in decompensated heart failure Human RCT
- Outpatient serial infusions for advanced chronic heart failure Human observational
- Acute myocardial infarction complicated by heart failure Human RCT
- Potential future application — acute coronary syndromes, pulmonary hypertension, and antifibrotic/anti-remodeling therapy Mechanistic only
Safety signals
- Symptomatic hypotension
- Worsening renal function — historical controversy resolved by ASCEND-HF
- Mortality signal — historical concern not confirmed in definitive trial
- Lack of proven mortality benefit or reduction in rehospitalization
- Contraindication in cardiogenic shock and low-output states
- Headache
- Non-arrhythmogenic profile — safety advantage versus dobutamine
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Unspecified | 2 mcg/kg IV bolus, followed by 0.01 mcg/kg/min continuous IV infusion | — | Adults hospitalized with acute decompensated CHF — FDA-approved standard regimen | Research |
| Unspecified | Bolus doses of 0.5–2 mcg/kg followed by infusions of 0.005–0.03 mcg/kg/min | — | Adults with ADHF — dose-ranging studies (VMAC and prior trials) | Research |
| Unspecified | Not specified in abstracts reviewed | — | Outpatient serial infusions — advanced chronic heart failure | Research |
| Unspecified | Not specified in abstract | — | Pediatric patients — investigational | Research |
| intravenous | 2 mcg/kg IV bolus, then 0.01 mcg/kg/min continuous IV infusion | single bolus followed by continuous infusion | adults hospitalized with acute decompensated heart failure with dyspnea at rest or minimal exertion, normotensive or hypertensive |
No peer-reviewed studies indexed for this peptide yet.